Rejected from Nature Cell Biology? The 7 Best Journals to Submit Next

Source: Clarivate JCR 2024, Nature Portfolio, Cell Press, EMBO Press, and Rockefeller University Press journal pages and guides for authors (accessed June 2026). Selectivity descriptors are editorial assessments, not published rates.

1. Nature Communications. This is the in-portfolio landing spot for technically excellent work that did not clear the flagship's conceptual-advance bar. Because it is a Nature-titled journal, a transfer carries your files and referee reports with no reformatting, which removes most of the friction of a fresh submission. It still wants broad significance, so this works best when the rejection was about degree of advance, not about whether the work matters.

2. Molecular Cell. If your contribution is a deep molecular mechanism, structure-function insight, or a regulatory circuit resolved at high detail, this Cell Press venue rewards exactly that. The bar is high and reviewers are demanding about mechanistic completeness, so it fits when the molecular story is the protagonist.

3. Science Advances. A strong broad-scope alternative outside the Nature and Cell Press systems. It suits work with genuine cross-field significance where the contribution is the finding's reach rather than the depth of a single mechanism, and it carries a respected name without requiring a Nature or Cell brand fit.

4. Developmental Cell. The cleanest home when the real story is developmental biology, morphogenesis, or stem-cell mechanism. Reviewers here are specifically demanding about developmental logic, not just whether the experiments work, so it fits when the developmental reasoning is airtight and central.

5. EMBO Journal. Publishes mechanistic molecular cell biology with an emphasis on conceptual advance and physiological relevance. It is slightly broader than Molecular Cell in approach and model system, and it is a good fit when the work has clear mechanistic significance beyond a narrow specialist audience.

6. Cell Reports. The pragmatic choice for sound, complete advances that do not need to be a singular conceptual leap. It values rigor and completeness over breakthrough framing, so it is a sensible step down for solid work that just needs an efficient, well-cited broad home.

7. Journal of Cell Biology. The specialist venue for imaging-rich, quantitative, mechanism-first basic cell biology. Editors prioritize imaging quality, quantitative single-cell measurement, and durable mechanistic conclusions over general appeal, so it fits manuscripts whose strength is rigorous quantitative cell biology rather than maximum breadth.

Nature Cell Biology participates in the Nature portfolio manuscript transfer service, and a rejecting editor can offer a few-click transfer that carries your manuscript files, and often the referee reports and referee identities, to another Nature-titled journal. For transfers between Nature-titled journals there is no need to re-enter submission information and no reformatting, and the receiving editor can use the existing referee comments to speed a decision.

The most common destination after a Nature Cell Biology rejection is Nature Communications. In the event the work is judged unsuitable, an editor may also consult colleagues across the portfolio to recommend a more suitable Nature journal. You can accept a transfer, decline all suggestions, or ignore the offer and submit manually. A transfer offer is a routing suggestion, not a quality endorsement, so treat the destination as you would any other target.

Practical ladder by rejection reason:

• Editorially rejected without review for scope or breadth (too narrow, or really developmental biology, immunology, or biochemistry in disguise)? Do not transfer to a broad-significance Nature journal unchanged. The breadth problem follows the paper. Pick the journal whose scope actually matches the work: Developmental Cell, Journal of Cell Biology, EMBO Journal, or Molecular Cell.

• Rejected for insufficient conceptual advance but sound, broadly relevant science? This is the classic transfer or step-down case.

Nature Communications is the next tier inside the portfolio; Science Advances or Cell Reports are strong outside it. Accept a transfer offer here if the suggested journal fits.

• Rejected after review because the mechanism was inferred, not demonstrated, or a key control was missing? Fix it before resubmitting anywhere. Every serious cell-biology venue will raise the same functional-evidence point. Carry the new experiment and revised conclusions into the transfer or the manual resubmission.

In our pre-submission review work with Nature Cell Biology manuscripts, the rejections we see most often cluster into four named patterns. Each is journal-specific and testable against your own manuscript, which is what makes them worth checking before you resubmit anywhere.

Mechanism inferred from correlation instead of shown by functional evidence. Across our Nature Cell Biology pre-submission reviews, the single most common editorial trigger is a central mechanistic claim supported by localization, co-immunoprecipitation, or expression correlation, with no loss-of-function or rescue experiment that proves the protein actually drives the process. A manuscript states "protein X regulates pathway Y" but the strongest data are that X is present when Y happens.

Nature Cell Biology editors expect the mechanism to be demonstrated, not inferred, so they reject this without review. The fix is a clean functional perturbation, a knockdown or knockout with a rescue, that ties the molecule to the phenotype. This is testable: look at your central claim and ask whether removing or restoring the protein changes the outcome in your own figures, or whether you are relying on association.

Phenomenon described without a mechanistic model. A second recurring pattern in the Nature Cell Biology manuscripts we review is a careful, correct description of a cellular observation, more of a behavior, a new structure, a stress response, with no model of how it works at the molecular level. The editorial question at this journal is not "is this real?" but "do we now understand something we did not before?"

Reviewers and editors consistently flag the gap between a documented phenomenon and an explained one. The fix is either the mechanistic experiments that turn description into insight, or an honest reframing toward a more descriptive-friendly venue. Check whether your discussion explains the mechanism or mainly restates the result.

Breadth and scope drift. The third pattern is a technically strong study whose significance is real but narrow, or whose true center of gravity is developmental biology, immunology, neurobiology, or biochemistry rather than core cell biology. The journal wants broad interest to the whole cell-biology community, so a paper that only matters to a small subfield is filtered fast regardless of quality.

Read your own abstract and ask: would a cell biologist outside my immediate area care, and is cell-biological mechanism the actual protagonist or a wrapper around another field's question? If it is narrow or a wrapper, the right move is a better-fit journal, not an appeal.

Incomplete functional package and weak controls. The fourth pattern is a paper where the story is promising but the supporting experiments are not yet airtight: a key claim rests on a single approach, controls for off-target effects or specificity are missing, or the quantification does not support the stated effect size.

A figure-heavy manuscript with many supplementary panels but no single clean experiment that nails the main point is a red flag, because it usually means the central result cannot stand on its own. Check that every headline claim has an orthogonal validation and a matched control, and that the statistics fit the experimental design.

Don't just resubmit the same file down the ladder. The fastest way to collect a second rejection is to send an unrevised manuscript to a journal that screens for the same thing Nature Cell Biology did, and some manuscripts need real work, not a faster next submission.

An editorial rejection for scope or breadth is a routing problem you can fix by choosing the right journal and rewriting the cover letter and abstract to its priorities. A post-review rejection for inferred mechanism or a missing control is a substance problem, and the same concern will reappear at any serious venue. Be honest about which one you got.

Two cases call for real work before resubmitting. First, if reviewers questioned whether the mechanism was demonstrated, the manuscript needs the functional perturbation and rescue it was missing, and that often means new experiments, not new prose. Second, if specificity or controls were challenged, new validation is the only fix.

Appealing is rarely worth it: an insufficient-conceptual-advance or narrow-scope rejection is an editorial judgment, not a factual error, and the appeal queue is slower than a clean resubmission to a better-fit journal. Reserve an appeal for a genuine factual error or a reviewer who clearly misread the data.